Value of MDSC level and NLR/PLR ratio in peripheral blood of patients with colorectal cancer in guiding clinical prognosis evaluation

doi:10.3877/cma.j.issn.2095-1221.2019.03.004

Abstract

Abstract:

Objective

To explore the value of Myeloid-derived suppressor cell (MDSC) level in peripheral blood, neutrophil to lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR) in guiding clinical prognosis evaluation of patients with colorectal cancer.

Methods

183 patients with colorectal cancer and 50 health examinees admitted to our hospital from May 2013 to May 2018 were enrolled in the patient group and the control group respectively. The levels of MDSC and the ratio of NLR to PLR in peripheral blood of patients before and after treatment were measured. The changes of the above indexes in patients before and after treatment were recorded, and the differences of the above indexes in patients with effective and ineffective treatment before treatment were compared. Chi-square test, t-test and receiver operating characteristic (ROC) were used for statistical analysis.

Results

Before treatment, the ratio of MDSC, NLR and PLR in patients group were (4.26±0.99) ﹪, (3.05±0.59) , (146.45±29.71) respectively, which were higher than those in the control group (0.71 ±0.15) ﹪, (1.62 ±0.37) , (90.92 ±13.88) . The difference was statistically significant (t?= 25.238, 16.272, 12.824, P all < 0.05) . The ratio of MDSC, NLR and PLR decreased one month after treatment, and the difference was statistically significant (P < 0.05) . Among 183 patients, 111 cases were included in the effective treatment group and 72 cases were included in the ineffective treatment group. The ratio of MDSC, NLR and PLR in the effective group before treatment were (4.06±0.61) ﹪, (2.73±0.40) , (136.18±26.11) , respectively, which were lower than those in the ineffective group (4.57±0.42) ﹪, (3.54±0.31) , (162.29±18.64) , respectively (t?= 6.202, 14.572, 7.353, P all < 0.05) . ROC curve showed that the area under the curve of MDSC (> = 4.22﹪) , NLR (> = 3.21) , PLR (> = 151.60) before treatment was 0.909 (P < 0.05) .

Conclusion

The level of MDSC and the ratio of NLR to PLR of the peripheral blood in patients with colorectal cancer are significantly increased, and the higher MDSC level and the ratio of NLR to PLR imply poor prognosis.

Key words: Colorectal cancer, Myelogenous suppressor cells, Neutrophil-lymphocyte ratio, Platelet-lymphocyte ratio, Prognostic evaluation

Yijian Li, Shibiao Zhong, Shengchen Li. Value of MDSC level and NLR/PLR ratio in peripheral blood of patients with colorectal cancer in guiding clinical prognosis evaluation[J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2019, 09(03): 149-153.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxbygxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-1221.2019.03.004

https://zhxbygxbzz.cma-cmc.com.cn/EN/Y2019/V09/I03/149

Figures/Tables 5

References 18

[1]	Kumar V,Patel S,Tcyganov E, et al. The Nature of Myeloid-Derived suppressor cells in the tumor microenvironment[J]. Trends Immunol, 2016, 37(3):208-220.
[2]	Veglia F,Perego M,Gabrilovich D. Myeloid-derived suppressor cells coming of age[J]. Nat Immunol, 2018, 19(2):108-119.
[3]	张勇超,谢建国,韩广森, 等. 直肠癌患者外周血髓源抑制细胞的检测及其临床意义[J]. 中华胃肠外科杂志, 2017, 20(7):798-802.
[4]	全雄男,朴美华,刘兰. 术前NLR与PLR对结直肠癌预后的意义[J]. 中国肿瘤外科杂志, 2016, 8(6):369-372.
[5]	Chun E,Lavoie S,Michaud M, et al. CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid-derived suppressor cell population and function[J]. Cell Rep, 2015, 12(2):244-257.
[6]	Inamoto S,Itatani Y,Yamamoto T, et al. Loss of SMAD4 promotes colorectal cancer progression by accumulation of Myeloid-Derived suppressor cells through the CCL15-CCR1 chemokine axis[J]. Clin Cancer Res, 2016, 22(2):492-501.
[7]	Pinton L,Solito S,Damuzzo V, et al. Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression[J]. Oncotarget, 2016, 7(2):1168-1184.
[8]	王永仿,许联红,恽志华, 等. 结直肠癌患者外周血G-MDSC和M-MDSC水平与疗效的相关性分析[J]. 细胞与分子免疫学杂志, 2018, 34(6):70-75.
[9]	Ouyang LY,Wu XJ,Ye SB, et al. Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer[J]. J Transl Med, 2015, 13(1):47.
[10]	Umansky V,Blattner C,Gebhardt C, et al. The role of Myeloid-Derived suppressor cells (MDSC) in cancer progression[J]. Vaccines, 2016, 4(4):36.
[11]	张勇超,李潜,谢建国, 等. 直肠癌及癌前病变患者外周血髓源抑制细胞的表达及其临床意义[J]. 癌症进展, 2018, 16(4):503-505.
[12]	Hossain F,Al-Khami AA,Wyczechowska D, et al. Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies[J]. Cancer Immunol Res, 2015, 3(11):1236-1247.
[13]	邱琛. 奥沙利铂对结直肠癌肿瘤微环境中MDSCs分化调控的影响及机制初探[D]. 广州: 南方医科大学, 2017 .
[14]	王国振. 髓源抑制性细胞对结直肠癌发生发展的影响及机制初探[D]. 广州: 南方医科大学, 2015 .
[15]	Kilincalp S,Coban S,Akinci H, et al. Neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and mean platelet volume as potential biomarkers for early detection and monitoring of colorectal adenocarcinoma[J]. Eur J Cancer Prev, 2015, 24(4):328-333.
[16]	Zou ZY,Liu HL,Ning N, et al. Clinical significance of pre-operative neutrophil lymphocyte ratio and platelet lymphocyte ratio as prognostic factors for patients with colorectal cancer[J]. Oncol Lett, 2016, 11(3):2241-2248.
[17]	陈小林,姚国强,刘剑荣. 术前外周血中NLR、d-NLR、PLR和LMR四种比值在结直肠癌患者预后诊断中的价值[J]. 中国免疫学杂志, 2015, 31(10):1389-1393.
[18]	Koh CH,Bhoo-Pathy N,Ng KL, et al. Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer[J]. Br J Cancer, 2015, 113(1):150-158.

分组	例数	MDSC（﹪）	NLR	PLR
患者组	183	4.26±0.99	3.05±0.59	146.45±29.71
对照组	50	0.71±0.15	1.62±0.37	90.92±13.88
t值	?	25.238	16.272	12.824
P值	?	< 0.01	< 0.01	< 0.01

分组	例数	MDSC（﹪）	NLR	PLR
患者组	183	4.26±0.99	3.05±0.59	146.45±29.71
对照组	50	0.71±0.15	1.62±0.37	90.92±13.88
t值	?	25.238	16.272	12.824
P值	?	< 0.01	< 0.01	< 0.01

时期	例数	MDSC（﹪）	NLR	PLR
治疗前	183	4.26±0.99	3.05±0.59	146.45±29.71
治疗后1个月	183	2.28±0.42	2.27±0.39	118.65±25.30
t值	?	24.907	14.919	9.637
P值	?	< 0.01	< 0.01	< 0.01

时期	例数	MDSC（﹪）	NLR	PLR
治疗前	183	4.26±0.99	3.05±0.59	146.45±29.71
治疗后1个月	183	2.28±0.42	2.27±0.39	118.65±25.30
t值	?	24.907	14.919	9.637
P值	?	< 0.01	< 0.01	< 0.01

指标	截断值	灵敏度（﹪）	特异性（﹪）	曲线下面积
MDSC	≥4.22﹪	87.90	86.82	0.881
NLR	≥3.21	85.06	87.99	0.878
PLR	≥151.60	81.74	85.06	0.824
MDSC＋NLR＋PLR	?	90.13	88.25	0.909

Please choose a citation manager

Content to export